Patents by Inventor Andrew Kotliar

Andrew Kotliar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6800647
    Abstract: This invention encompasses a pharmaceutical composition comprising the compound of formula A: in combination with a pharmaceutically acceptable carrier, said compound being comprised of about 1-50%, 1-20% or 1-10% of the polymorphic form which is designated Form V and the remainder of the compound being comprised of at least one polymorphic form selected from the group consisting of: Form I, Form II, Form III and Form IV.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: October 5, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Loius S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Patent number: 6673935
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: which is useful in the treatment of cyclooxygenase-2 mediated diseases. The invention encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising the Form V polymorph of Compound A. The invention also encompasses a process for synthesizing the Form V polymorph of Compound A.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: January 6, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Patent number: 6632836
    Abstract: The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 14, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Jennifer Chee, Maria L. Garcia, Gregory J. Kaczorowski, Frank Kayser, Andrew Kotliar, Chou Juitsai Liu, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht, William A. Schmalhofer, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Publication number: 20030153600
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: 1
    Type: Application
    Filed: January 14, 2003
    Publication date: August 14, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Patent number: 6521642
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: which is useful in the treatment of cyclooxygenase-2 mediated diseases. The invention encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising the Form V polymorph of Compound A. The invention also encompasses a process for synthesizing the Form V polymorph of Compound A.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: February 18, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Publication number: 20020147221
    Abstract: This invention encompasses a pharmaceutical composition comprising the compound of formula A: 1
    Type: Application
    Filed: September 21, 2001
    Publication date: October 10, 2002
    Inventors: Loius S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Publication number: 20020016343
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: 1
    Type: Application
    Filed: May 25, 2001
    Publication date: February 7, 2002
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Patent number: 6303637
    Abstract: The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 16, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Andrew Kotliar, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Patent number: 6194458
    Abstract: This invention relates to benzamide potassium channel inhibitors of general structural Formula I. The compounds of this invention are useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and related afflictions, diseases and illnesses, and cardiac arrhythmias. Also within the scope of this invention are pharmaceutical formulations comprising a compound of Formula I and a pharmaceutical carrier, as well as pharmaceutical formulations comprising a compound of Formula I, one or more immunosuppressive compounds and a pharmaceutical carrier.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: February 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Frank Kayser, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Patent number: 6022890
    Abstract: The compounds of Formula I ##STR1## are useful as immunosuppressive agents.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: February 8, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Robert K. Baker, Frank Kayser, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht, Peter J. Sinclair
  • Patent number: 5998408
    Abstract: The compounds of Formula I ##STR1## are useful as immunosuppressive agents.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: December 7, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Frank Kayser, Jianming Bao, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht
  • Patent number: 5952371
    Abstract: The compounds of Formula I ##STR1## are useful as iumnunosuppressive agents.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: September 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Frank Kayser, Jianming Bao, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht
  • Patent number: 5874594
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: February 23, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Frank Kayser, Jianming Bao, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht
  • Patent number: 5670504
    Abstract: A class of 2,6-diarylpyridazinones of general structural formula I have been identified that exhibit exhibit immunosuppressant activity with human T-lymphocytes, and are useful as an immunosuppressants.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: September 23, 1997
    Assignee: Merck & Co. Inc.
    Inventors: Richard J. Bochis, Andrew Kotliar, William H. Parsons, Kathleen Rupprecht